Evaluation of acute Myeloid Leukaemia (AML) at the time of diagnosis, to assist in appropriate classification and prognosis using five translocation gene panel and karyotyping.
This reflex test sequentially evaluates for the common major gene mutations associated with non-BCR/ABL1-positive myeloproliferative neoplasms until a mutation is identified.
Diagnostic workup of patients with a high probability of BCR-ABL1-positive hematopoietic neoplasms, particularly acute lymphoblastic leukaemia (B-lymphoblastic leukaemia), to provide a pre-treatment quantitative level of BCR-ABL1 mRNA transcript if the initial diagnostic RT-PCR screen is positive
Factor V Leiden mutation testing should be reserved for patients with clinically suspected thrombophilia and: 1) APC-resistance proven or suspected by a low or borderline APC-resistance ratio, or 2) a family history of factor V Leiden.
Direct mutation analysis for the MTHFR C677T and A1298C mutations should be reserved for patients with coronary artery disease, acute myocardial infarction, peripheral vascular artery disease, stroke, or venous thromboembolism who have increased basal homocysteine levels or an abnormal methionine-load test.
